Accentia Biopharmaceuticals, Inc. (ABPI)

Last Trade:	4.45
Trade Time:	11:28AM ET
Change:	1.57 (54.51%)

Accentia Biopharmaceuticals: New study shows use of a BiovaxID formulation improves disease free survival in 80% of patients Co announces that a new study by Dr. Susana Inoges and colleagues at the University of Navarra has shown that the administration of a BiovaxID formulation given to patients with relapsed Follicular Non-Hodgkins Lymphoma following chemotherapy, with or without concomitant Rituxan, can induce complete long-lasting remissions. Moreover, these second remissions are uniquely characterized by a duration that exceeds the duration of the first remission. In the study, 80% of patients achieved an immune response to the Biovaxid formulation, and among these responders, the median time of complete tumor remission has not been reached after 33 months of mean follow-up.